Giant Biogene Holding Co (HKSE:02367) Cash Conversion Cycle : 59.27 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Giant Biogene Holding Co's Days Sales Outstanding for the six months ended in Dec. 2023 was 8.19.
Giant Biogene Holding Co's Days Inventory for the six months ended in Dec. 2023 was 109.55.
Giant Biogene Holding Co's Days Payable for the six months ended in Dec. 2023 was 58.47.
Therefore, Giant Biogene Holding Co's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2023 was 59.27.

Giant Biogene Holding Co Cash Conversion Cycle Historical Data

The historical data trend for Giant Biogene Holding Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Cash Conversion Cycle Chart

Giant Biogene Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Conversion Cycle

70.83

69.79

103.85

109.45

70.17

Giant Biogene Holding Co Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Cash Conversion Cycle	Get a 7-Day Free Trial			-	98.37	113.34	96.19	59.27

Competitive Comparison of Giant Biogene Holding Co's Cash Conversion Cycle

For the Household & Personal Products subindustry, Giant Biogene Holding Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Giant Biogene Holding Co's Cash Conversion Cycle Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Giant Biogene Holding Co's Cash Conversion Cycle falls into.

Giant Biogene Holding Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Giant Biogene Holding Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	7.14	+	122.78	-	59.75
	=	70.17

Giant Biogene Holding Co's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	8.19	+	109.55	-	58.47
	=	59.27

Giant Biogene Holding Co (HKSE:02367) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Giant Biogene Holding Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Giant Biogene Holding Co (HKSE:02367) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN

Website

http://www.xajuzi.com

Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

Executives

Refulgence Holding Limited	2201 Interest of corporation controlled by you
Juzi Holding Co., Ltd	2101 Beneficial owner
Fan Daidi	2201 Interest of corporation controlled by you
Yan Jianya	2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Yan Jianya	2101 Beneficial owner
Fan Daidi
Trident Trust Company (b.v.i.) Limited	2301 Trustee

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines